ADMA ADMA Biologics Inc

4.94
-0.03  -0.6%
Previous Close 4.97
Open 5.19
Price To book 0.00
Market Cap 63.66M
Shares 12,886,000
Volume 22,111
Short Ratio 2.25
Av. Daily Volume 30,776

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

CRL issued July 29 2016. Third-party manufacturing issues cited.
RI-002
Primary Immune Deficiency Diseases

Latest News

  1. ADMA BIOLOGICS, INC. Files SEC form 8-K, Change in Directors or Principal Officers
  2. ADMA BIOLOGICS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Unregistered Sale of Equity Secu
  3. ADMA Biologics upgraded by Maxim Group
  4. ADMA Biologics to Acquire Certain Assets from Biotest Pharmaceuticals Corporation and Become a Vertically Integrated Commercial Plasma Products Company
  5. ADMA Biologics Inc (ADMA): Does It Stack Up To Its Peers?
  6. ADMA: Incremental Progress on CMC Issue Resolution.
  7. ADMA BIOLOGICS, INC. Financials
  8. ETFs with exposure to ADMA Biologics, Inc. : November 16, 2016
  9. ADMA Biologics, Inc. :ADMA-US: Earnings Analysis: Q3, 2016 By the Numbers : November 14, 2016
  10. ADMA BIOLOGICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhi
  11. ADMA BIOLOGICS, INC. Files SEC form 8-K, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Financial S
  12. ETF’s with exposure to ADMA Biologics, Inc. : September 21, 2016
  13. ADMA BIOLOGICS, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
  14. ADMA - Reviewing 2Q:16 Results; Waiting for Clarity on Resubmission Timeline
  15. ADMA Biologics, Inc. :ADMA-US: Earnings Analysis: Q2, 2016 By the Numbers : August 16, 2016
  16. ADMA BIOLOGICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhi
  17. ADMA BIOLOGICS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits
  18. ADMA CRL Isolated to Partner Manufacturing Issues: Anticipate 8 Month Delay
  19. INVESTOR NOTICE: Goldberg Law PC Announces an Investigation of Claims against ADMA Biologics, Inc. and Advises Investors with Losses to Contact the Firm
  20. SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Regarding Possible Violations of Federal Securities Laws by Certain Officers and Directors of ADMA Biologics, Inc.